[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201692371A1 - 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений - Google Patents

1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений

Info

Publication number
EA201692371A1
EA201692371A1 EA201692371A EA201692371A EA201692371A1 EA 201692371 A1 EA201692371 A1 EA 201692371A1 EA 201692371 A EA201692371 A EA 201692371A EA 201692371 A EA201692371 A EA 201692371A EA 201692371 A1 EA201692371 A1 EA 201692371A1
Authority
EA
Eurasian Patent Office
Prior art keywords
naftyridin
antiproliferative compounds
compounds
antiproliferative
naphthyridin
Prior art date
Application number
EA201692371A
Other languages
English (en)
Inventor
Амала Компелла
Венугопала Кришна Гампа
Сринивасулу Ганганамони
Балакришна Редди Сириджиредди
Кали Сатья Бхуджанга Рао Адибхатла
Венкайах Човдари Наннапанени
Original Assignee
Натко Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Натко Фарма Лимитед filed Critical Натко Фарма Лимитед
Publication of EA201692371A1 publication Critical patent/EA201692371A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к новым антипролиферативным 1Н-1,8-нафтиридин-2-онам общей формулы (I) или их фармацевтически приемлемым солямв которых различные группы являются такими, как определено в настоящем документе, а также к их получению и применению в лечении заболеваний, связанных с ингибированием тирозинкиназ у теплокровных животных. Соединения способны преодолевать вызываемую иматинибом лекарственную устойчивость.
EA201692371A 2014-06-06 2014-12-15 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений EA201692371A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2781CH2014 2014-06-06
PCT/IN2014/000777 WO2015186137A1 (en) 2014-06-06 2014-12-15 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Publications (1)

Publication Number Publication Date
EA201692371A1 true EA201692371A1 (ru) 2017-04-28

Family

ID=52589723

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692371A EA201692371A1 (ru) 2014-06-06 2014-12-15 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений

Country Status (18)

Country Link
US (2) US9765072B2 (ru)
EP (1) EP3152205A1 (ru)
JP (1) JP2017516867A (ru)
KR (1) KR20170016921A (ru)
CN (1) CN106573929A (ru)
AP (1) AP2016009604A0 (ru)
AU (1) AU2014396394A1 (ru)
BR (1) BR112016028674A2 (ru)
CA (1) CA2950250A1 (ru)
CL (1) CL2016003102A1 (ru)
EA (1) EA201692371A1 (ru)
HK (1) HK1231469A1 (ru)
IL (1) IL249118A0 (ru)
MA (1) MA39524A1 (ru)
MX (1) MX2016015350A (ru)
PH (1) PH12016502432A1 (ru)
SG (1) SG11201610149YA (ru)
WO (1) WO2015186137A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201610149YA (en) * 2014-06-06 2017-01-27 Natco Pharma Ltd 1h-1,8- naphthyridin-2ones as anti proliferative compounds
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
CN108473476B (zh) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
CN101489558A (zh) * 2006-05-08 2009-07-22 阿里亚德医药股份有限公司 炔类杂芳基化合物
AU2007249924B2 (en) * 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2937345B1 (en) * 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
RU2524210C2 (ru) 2010-01-29 2014-07-27 Ханми Сайенс Ко., Лтд. ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
SG11201610149YA (en) * 2014-06-06 2017-01-27 Natco Pharma Ltd 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Also Published As

Publication number Publication date
US10047088B2 (en) 2018-08-14
EP3152205A1 (en) 2017-04-12
US9765072B2 (en) 2017-09-19
CL2016003102A1 (es) 2017-06-23
US20170114057A1 (en) 2017-04-27
AU2014396394A1 (en) 2016-12-08
AP2016009604A0 (en) 2016-12-31
SG11201610149YA (en) 2017-01-27
BR112016028674A2 (pt) 2017-08-22
MA39524A1 (fr) 2018-01-31
CA2950250A1 (en) 2015-12-10
PH12016502432A1 (en) 2017-03-06
US20170349588A1 (en) 2017-12-07
JP2017516867A (ja) 2017-06-22
MX2016015350A (es) 2017-05-10
KR20170016921A (ko) 2017-02-14
WO2015186137A1 (en) 2015-12-10
CN106573929A (zh) 2017-04-19
HK1231469A1 (zh) 2017-12-22
IL249118A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
EA201790413A1 (ru) Антитела против tigit
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201792116A1 (ru) Ингибитор янус-киназы
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
EA201692470A1 (ru) Фармацевтические комбинации
EA201600434A1 (ru) Применение производных бензимидазолпролина
TW201613577A (en) Pharmaceutical combinations
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EA202190281A1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования